Latest News
Sobi presents phase 3 gout study results for pozdeutinurad
29 October 2026 - Swedish biopharmaceutical company Swedish Orphan Biovitrum AB (Sobi) (STO: SOBI) on Thursday reported late-breaking data from the phase 3 REDUCE-2 study showing that investigational gout treatment pozdeutinurad (AR882) delivered sta...
Celularity and Vesalius sign exclusive US peptide manufacturing agreement
29 October 2026 - Celularity Inc (Nasdaq:CELU), a longevity-focused regenerative and cellular medicine company, and Vesalius Longevity Labs Inc, a global peptide and longevity brand, announced on Thursday that they have signed an exclusive manufactur...
Daiichi Sankyo secures EMA validation for two triple-combination cholesterol therapies
29 October 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Thursday that it has received European Medicines Agency (EMA) validation for two marketing authorisation applications covering single-pill triple-combination ...
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
29 October 2026 - Biotechnology company TME Pharma N.V. (Euronext Growth Paris:ALTME) said on Thursday that it has signed a binding exclusive negotiation agreement with Japanese clinical-stage biotechnology company TMS Co Ltd to negotiate a definitiv...
Formation Bio establishes USD600m debut fund for drug development
29 October 2026 - Formation Bio, a New York-based, AI-native pharmaceutical company, announced on Wednesday the Formation Bio Drug Development Accelerator Fund with USD600m in capital commitments.This fund is designed to expand the company's por...